Biogen reported $10.0B of revenue over the trailing twelve months, +0.31% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $10.0B (to Q2 2026). Net income: $835M, trailing twelve months to Q2 2026. Free cash flow: $2.70B, trailing twelve months to Q2 2026. Operating margin: 9.9%, trailing twelve months to Q2 2026.

BIIBBiogen

Healthcare

$250.76+76% 1Y

$250.76

$143.0052 weeks$253.90

BIIB as reported

Biogen reported $10.0B of revenue over the trailing twelve months, +0.31% on the year before. 11 reported series are charted on this page, each one as filed.

$10.0B

Revenue, trailing twelve months · to Q2 2026 · +0.31% against the twelve months before

Net income: $835M
Net income · −45% year on year · trailing twelve months to Q2 2026
Free cash flow: $2.70B
Free cash flow · +36% year on year · trailing twelve months to Q2 2026
Operating margin: 9.9%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BIIB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$10.0B	+0.31%	Q2 2026
Net income	$835M	−45%	Q2 2026
EPS	$5.63	−46%	Q2 2026
Gross margin	74%	n/a	Q2 2026
Operating margin	9.9%	n/a	Q2 2026
Net margin	8.2%	n/a	Q2 2026
ROE	6.9%	n/a	Q2 2026
ROA	4.3%	n/a	Q2 2026
ROIC	5.6%	n/a	Q2 2026
Free cash flow	$2.70B	+36%	Q2 2026
P/E	44.5	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.